Learning Objectives: 

1.) Review the pathophysiology of disease in eGPA and identify targets for biologic therapies.

2.) Review the results of the MIRRA trial and how this influenced the need for this study.

3.) Describe which biologics are being prescribed for different eGPA manifestations, as well as the efficacy and safety for the therapies studied in this review.

Disclosures:

- None

CME Code: QANYOW

Location: virtual (by WebEx only)
Directions: If you are having trouble accessing WebEx, please contact Isaac Smith at isaac.smith063@duke.edu. 

 Streaming: Yes, via WebEx. Link:  https://dukemed.webex.com/meet/is120 

Meeting Number/Access Code: 470 543 135  (you will not need this if you use link above)

Call-in number: 1-650-479-3207